ZCA
TLSI icon

Zeke Capital Advisors’s TriSalus Life Sciences TLSI Stock Holding History

Zeke Capital Advisors’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200,000
Closed -$1.99M – 536
2022
Q3 		$1.99M Hold
200,000
– – 0.14% 71
2022
Q2 		$1.97M Buy
+200,000
New +$1.97M 0.13% 77

Other funds holding TLSI

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
DFCM
Dark Forest Capital Management San Juan, Puerto Rico $1.13B AUM 18.74% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Zeke Capital Advisors's TLSI Position: Q4 2022 in Review

Zeke Capital Advisors sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 200,000 shares — an estimated $1.99M sold.

Zeke Capital Advisors first reported a position in TLSI in Q2 2022 and held it in 2 quarters. The position peaked at $1.99M in Q3 2022. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

  • Zeke Capital Advisors reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Zeke Capital Advisors sold 200,000 TriSalus Life Sciences shares in Q4 2022, an estimated $1.99M.
  • Zeke Capital Advisors first reported a position in TriSalus Life Sciences in Q2 2022 and held it in 2 quarters.
  • Zeke Capital Advisors's TriSalus Life Sciences position peaked at $1.99M in Q3 2022.
  • 9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.